Skip to content
RushPR News – Lifestyle
Author:
Transgene S.A.
Transgene Provides Business and Financial Update for Q1 2026
April 29, 2026
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
April 13, 2026
Availability of Transgene’s 2025 Universal Registration Document (URD)
April 9, 2026
Transgene Continues Progress to Reshape Early-Stage Cancer Treatment through Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility Until Early 2028
March 24, 2026
←
Previous Page
1
2